-
Posted by
Two Blokes Jul 16 -
Filed in
Stock
-
1 view
AstraZeneca PLC (LSE:AZN) shares opened lower on Wednesday after a late-stage trial of its experimental treatment for AL amyloidosis failed to meet its primary target in the overall patient group. The CARES phase III study tested anselamimab, a drug designed to clear harmful protein deposits in organs.
